Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Astrana Health (NASDAQ:ASTH) and its peers.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Even during a down period for the markets, Privia Health has gone against the grain, climbing to $22.91. Its shares have yielded a 29.3% return over the last six months, beating the S&P 500 by 30.9%. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 9.8%. This performance was worse than the S&P 500’s 1.6% decline.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Phreesia (NYSE:PHR) and its peers.
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Healthcare tech company Privia Health Group (NASDAQ:PRVA) announced better-than-expected revenue in Q4 CY2024, with sales up 4.6% year on year to $460.9 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.21 per share was in line with analysts’ consensus estimates.
